R130
RJR-2403 hemigalactarate
≥98% (HPLC), powder
别名:
N-Methyl-4-(3-pyridinyl]-3-buten-1-amine hemigalactarate
登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C20H28N4 · C6H10O8
化学文摘社编号:
分子量:
534.60
UNSPSC Code:
12352200
MDL number:
SMILES string
CNCC\C=C\c1cccnc1
assay
≥98% (HPLC)
form
powder
color
white
solubility
DMSO: 1 mg/mL, H2O: 20 mg/mL
storage temp.
2-8°C
Biochem/physiol Actions
Neuronal nicotinic acetylcholine receptor agonist that displays CNS activity.
Disclaimer
Photosensitive
法规信息
新产品
此项目有
Pharmacological characterization of RJR-2403: A nicotinic agonist with potential therapeutic benefit in the treatment of Alzheimer's disease.
Bencherif, M.
Cns Drug Reviews, 3, 325-325 (1997)
P M Lippiello et al.
The Journal of pharmacology and experimental therapeutics, 279(3), 1422-1429 (1996-12-01)
We have evaluated the physiological and behavioral effects of the CNS-selective nicotinic agonist (E)-N-methyl-4-(3-pyridinyl) -3-butene-1-amine (RJR-2403) using a number of different methods, including 1) reversal of pharmacologically induced amnesia in a step-through passive avoidance paradigm, 2) radial arm maze performance
K L Summers et al.
Neurochemical research, 21(10), 1181-1186 (1996-10-01)
Transcortical dialysis was employed to investigate the effects of subcutaneous (s.c.) injections of RJR-2403 (1.2-7.2 mumol/kg) on extracellular levels of acetylcholine (ACh), norepinephrine (NE), dopamine (DA), and serotonin (5-HT) in rat. Systemic administration of RJR-2403 produced a 90% increase of
M Bencherif et al.
The Journal of pharmacology and experimental therapeutics, 279(3), 1413-1421 (1996-12-01)
Increasing evidence for an involvement of nicotinic cholinergic systems in neurodegenerative disorders has stimulated the search for compounds with selectivity for CNS nicotinic ACh receptors (nAChRs). To this end, we have evaluated a number of nicotinic agonists for their ability
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持